CA3187827A1 - Modified release formulations of modified forms of trimetazidine - Google Patents

Modified release formulations of modified forms of trimetazidine

Info

Publication number
CA3187827A1
CA3187827A1 CA3187827A CA3187827A CA3187827A1 CA 3187827 A1 CA3187827 A1 CA 3187827A1 CA 3187827 A CA3187827 A CA 3187827A CA 3187827 A CA3187827 A CA 3187827A CA 3187827 A1 CA3187827 A1 CA 3187827A1
Authority
CA
Canada
Prior art keywords
hours
imb
trimetazidine
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3187827A
Other languages
English (en)
French (fr)
Inventor
Andrew D. Levin
Jaikrishna Patel
George MOONEY
Scott Herbig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of CA3187827A1 publication Critical patent/CA3187827A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3187827A 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine Pending CA3187827A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063046117P 2020-06-30 2020-06-30
US202063046115P 2020-06-30 2020-06-30
US63/046,117 2020-06-30
US63/046,115 2020-06-30
US202163183299P 2021-05-03 2021-05-03
US202163183294P 2021-05-03 2021-05-03
US63/183,299 2021-05-03
US63/183,294 2021-05-03
PCT/US2021/039303 WO2022005926A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Publications (1)

Publication Number Publication Date
CA3187827A1 true CA3187827A1 (en) 2022-01-06

Family

ID=79315460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3187827A Pending CA3187827A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Country Status (8)

Country Link
EP (1) EP4171232A4 (https=)
JP (1) JP2023531802A (https=)
KR (1) KR20230028535A (https=)
CN (1) CN116234555A (https=)
AU (1) AU2021299197A1 (https=)
CA (1) CA3187827A1 (https=)
IL (1) IL299544A (https=)
WO (1) WO2022005926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466371B (zh) * 2006-06-09 2011-10-05 施瓦茨制药有限公司 含非索罗定的稳定的药用组合物
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
NZ745921A (en) * 2016-03-09 2021-12-24 Nls 1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Also Published As

Publication number Publication date
EP4171232A1 (en) 2023-05-03
IL299544A (en) 2023-02-01
JP2023531802A (ja) 2023-07-25
WO2022005926A1 (en) 2022-01-06
KR20230028535A (ko) 2023-02-28
CN116234555A (zh) 2023-06-06
AU2021299197A1 (en) 2023-02-02
EP4171232A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
ES2606050T5 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
TWI381835B (zh) 經修飾釋放之含１-〔（３-羥基-金剛烷-１-基胺基）-乙醯基〕-吡咯啶-２（ｓ）-腈調配物
EP3720433B1 (en) Bis-choline tetrathiomolybdate for treating wilson disease
UA75027C2 (uk) Спосіб лікування серцево-судинних захворювань лікарською формою ранолазину пролонгованої дії
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
JP2020525436A (ja) 胃耐性制御放出経口剤形
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
CA3187827A1 (en) Modified release formulations of modified forms of trimetazidine
US20230263786A1 (en) Modulation of drug-drug interactions of vadadustat
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
US20070053975A1 (en) Ramipril formulation
JP2024540172A (ja) 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法
US20160045497A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US20240148707A1 (en) Modulation of drug-drug interactions of vadadustat
EP4640213A1 (en) Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
Tablets et al. PrTEVA-DILTIAZEM XC
INC PrM-NIFEDIPINE ER
Standard et al. PRMYLAN-VERAPAMIL SR
Tablets et al. Pr SANDOZ SAXAGLIPTIN
EA047001B1 (ru) Лекарственные формы малеата акалабрутиниба
Agent KOMBOGLYZE®
US20070185180A1 (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250626

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250828

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250828

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250828

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250828